COSCIENS Biopharma Inc. Quarterly Research And Development Expense in USD from Q2 2018 to Q4 2024

Taxonomy & unit
ifrs-full: USD
Summary
COSCIENS Biopharma Inc. quarterly/annual Research And Development Expense history and growth rate from Q2 2018 to Q4 2024.
  • COSCIENS Biopharma Inc. Research And Development Expense for the quarter ending December 31, 2024 was $1.39M.
  • COSCIENS Biopharma Inc. Research And Development Expense for the twelve months ending December 31, 2024 was $8.3M, a 307% increase year-over-year.
  • COSCIENS Biopharma Inc. annual Research And Development Expense for 2024 was $8.3M, a 307% increase from 2023.
  • COSCIENS Biopharma Inc. annual Research And Development Expense for 2023 was $2.04M, a 48.8% increase from 2022.
  • COSCIENS Biopharma Inc. annual Research And Development Expense for 2022 was $1.37M, a 79.1% decline from 2021.
Research And Development Expense, Trailing 12 Months (USD)
Research And Development Expense, Quarterly (USD)
Research And Development Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $8.3M $1.39M +$4.49M Oct 1, 2024 Dec 31, 2024 20-F 2025-04-09
Q3 2024 $3.81M $2.8M +$2.36M +542% Jul 1, 2024 Sep 30, 2024 6-K 2024-11-12
Q2 2024 $1.45M $1.53M +$839K +121% Apr 1, 2024 Jun 30, 2024 6-K 2024-08-13
Q1 2024 $612K $2.58M -$1.43M -35.6% Jan 1, 2024 Mar 31, 2024 6-K 2024-05-16
Q4 2023 $2.04M -$3.1M +$3.61M +53.8% Oct 1, 2023 Dec 31, 2023 20-F 2025-04-09
Q3 2023 -$1.57M $436K -$2.86M -86.8% Jul 1, 2023 Sep 30, 2023 6-K 2024-11-12
Q2 2023 $1.29M $691K -$1.71M -71.2% Apr 1, 2023 Jun 30, 2023 6-K 2024-08-13
Q1 2023 $2.99M $4.01M +$1.62M +67.9% Jan 1, 2023 Mar 31, 2023 6-K 2024-05-16
Q4 2022 $1.37M -$6.71M -$8.57M -460% Oct 1, 2022 Dec 31, 2022 20-F 2025-04-09
Q3 2022 $9.94M $3.29M +$1.81M +122% Jul 1, 2022 Sep 30, 2022 6-K 2023-11-09
Q2 2022 $8.14M $2.4M +$630K +35.6% Apr 1, 2022 Jun 30, 2022 6-K 2023-08-09
Q1 2022 $7.51M $2.39M +$932K +63.9% Jan 1, 2022 Mar 31, 2022 6-K 2023-05-09
Q4 2021 $6.57M $1.86M +$1.24M +198% Oct 1, 2021 Dec 31, 2021 20-F/A 2024-07-17
Q3 2021 $5.34M $1.49M +$1.11M +299% Jul 1, 2021 Sep 30, 2021 6-K 2022-11-03
Q2 2021 $4.22M $1.77M +$1.58M +835% Apr 1, 2021 Jun 30, 2021 6-K/A 2022-08-04
Q1 2021 $2.65M $1.46M +$1.14M +357% Jan 1, 2021 Mar 31, 2021 6-K 2022-05-11
Q4 2020 $1.51M $626K +$363K +138% Oct 1, 2020 Dec 31, 2020 20-F/A 2024-02-15
Q3 2020 $1.14M $372K -$103K -21.7% Jul 1, 2020 Sep 30, 2020 6-K 2021-11-04
Q2 2020 $1.25M $189K -$382K -66.9% Apr 1, 2020 Jun 30, 2020 6-K 2021-08-05
Q1 2020 $1.63M $319K -$209K -39.6% Jan 1, 2020 Mar 31, 2020 6-K 2021-05-05
Q4 2019 $1.84M $263K Oct 1, 2019 Dec 31, 2019 20-F 2022-03-29
Q3 2019 $475K +$117K +32.7% Jul 1, 2019 Sep 30, 2019 6-K 2020-11-05
Q2 2019 $571K -$403K -41.4% Apr 1, 2019 Jun 30, 2019 6-K 2020-08-06
Q1 2019 $528K Jan 1, 2019 Mar 31, 2019 6-K/A 2020-05-11
Q3 2018 $358K Jul 1, 2018 Sep 30, 2018 6-K 2019-11-07
Q2 2018 $974K Apr 1, 2018 Jun 30, 2018 6-K 2019-08-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.